YaggiHKConcatoJKernanWNLichtmanJHBrassLMMohseninV. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353(19):2034–2041.
4.
Maurer-StrohSDebulpaepMKuemmererN. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods. 2010;7(3):237–242.
5.
NamtvedtSKRandbyAEinvikG. Cardiac arrhythmias in obstructive sleep apnea (from the Akershus Sleep Apnea Project). Am J Cardiol. 2011;108(8):1141–1146.
6.
KasaiTBradleyTD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57(2):119–127.
7.
GopalakrishnanPTakT. Obstructive sleep apnea and cardiovascular disease. Cardiol Rev. 2011;19(6):279–290.
8.
DartRAGregoireJRGuttermanDDWoolfSH. The association of hypertension and secondary cardiovascular disease with sleep-disordered breathing. Chest. 2003;123(1):244–260.
9.
EnglehardtJSwartoutJLoewenstineC. A new theoretical discrete growth distribution with verification for microbial counts in water. Risk Anal. 2009;29(6):841–856.
10.
CoughlinSRMawdsleyLMugarzaJAWildingJPCalverleyPM. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J. 2007;29(4):720–727.
11.
DasAMKhayatR. Hypertension in obstructive sleep apnea: risk and therapy. Expert Rev Cardiovasc Ther. 2009;7(6):619–626.
12.
BaguetJPBarone-RochetteGPepinJL. Hypertension and obstructive sleep apnoea syndrome: current perspectives. J Hum Hypertens. 2009;23(7):431–443.
13.
WangHLWangYZhangY. Changes in plasma angiotensin II and circadian rhythm of blood pressure in hypertensive patients with sleep apnea syndrome before and after treatment. Chin Med Sci J. 2011;26(1):9–13.
DragerLFBortolottoLAKriegerEMLorenzi-FilhoG. Additive effects of obstructive sleep apnea and hypertension on early markers of carotid atherosclerosis. Hypertension. 2009;53(1):64–69.
16.
MikhailidisDPElisafM, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
17.
MikhailidisDPElisafM, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
18.
SopkovaZBerneisKRizzoM. Low-density lipoproteins size and subclasses in patients with obstructive sleep apnea. Angiology. DOI: 10.1177/0003319711433811.
19.
DaskalopoulouSSAthyrosVGKolovouGDAnagnostopoulouKKMikhailidisDP. Definitions of metabolic syndrome: Where are we now?Curr Vasc Pharmacol. 2006;4(3):185–197.
20.
GaziITsimihodimosVFilippatosTBairaktariETselepisADElisafM. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism. 2006;55(7):885–891.
21.
TziomalosKAthyrosVGKaragiannisAMikhailidisDP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis. 2010;20(2):140–146.
22.
AthyrosVGMikhailidisDPPapageorgiouAA. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin. 2004;20(11):1691–1701.
23.
GaziIFFilippatosTDTsimihodimosV. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids. 2006;41(7):647–654.
24.
PeppardPEYoungTPaltaMSkatrudJ. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342(19):1378–1384.
25.
NietoFJYoungTBLindBK. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283(14):1829–1836.
26.
VgontzasANPapanicolaouDABixlerEO. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab. 2000;85(3):1151–1158.
27.
IpMSLamBNgMMLamWKTsangKWLamKS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002;165(5):670–676.
28.
DragerLFJunJCPolotskyVY. Metabolic consequences of intermittent hypoxia: relevance to obstructive sleep apnea. Best Pract Res Clin Endocrinol Metab. 2010;24(5):843–851.
29.
Kostoglou-AthanassiouIAthanassiouP. Metabolic syndrome and sleep apnea. Hippokratia. 2008;12(2):81–86.
30.
TanKCChowWSLamJC. HDL dysfunction in obstructive sleep apnea. Atherosclerosis. 2006;184(2):377–382.
31.
ChoNJooSKimJAbbottRDKimmKShinC. Relation of habitual snoring with components of metabolic syndrome in Korean adults. Diabetes Res Clin Pract. 2006;71(3):256–263.
32.
CoughlinSRMawdsleyLMugarzaJACalverleyPMWildingJP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J. 2004;25(9):735–741.
33.
GruberAHorwoodFSitholeJAliNJIdrisI. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol. 2006;5:22.
34.
VgontzasANBixlerEOChrousosGP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev. 2005;9(3):211–224.
35.
WilcoxIMcNamaraSGCollinsFLGrunsteinRR, Sullivan CE. “Syndrome Z”: the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax. 1998;53(suppl 3):S25–28.
LakkaTALaaksonenDELakkaHM. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sports Exerc. 2003;35(8):1279–1286.
38.
NewmanABNietoFJGuidryU. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol. 2001;154(1):50–59.
39.
PunjabiNMPolotskyVY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol. 2005;99(5):1998–2007.
40.
McArdleNHillmanDBeilinLWattsG. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med. 2007;175(2):190–195.
41.
LamJCIpMS. An update on obstructive sleep apnea and the metabolic syndrome. Curr Opin Pulm Med. 2007;13(6):484–489.
42.
JelicSLedererDJAdamsT. Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea. Vasc Health Risk Manag. 2009;5:909–920.
43.
El SolhAAAkinnusiMEBaddouraFHMankowskiCR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med. 2007;175(11):1186–1191.
44.
RossR. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
45.
LurieA. Endothelial dysfunction in adults with obstructive sleep apnea. Adv Cardiol. 2011;46:139–170.
46.
FengJZhangDChenB. Endothelial mechanisms of endothelial dysfunction in patients with obstructive sleep apnea. Sleep Breath. 2012;16(2):283–94.
47.
GjorupPHSadauskieneLWesselsJNyvadOStrungeBPedersenEB. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens. 2007;20(1):44–52.
48.
de la PenaMBarceloABarbeF. Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration. 2008;76(1):28–32.
49.
AtkesonAJelicS. Mechanisms of endothelial dysfunction in obstructive sleep apnea. Vasc Health Risk Manag. 2008;4(6):1327–1335.
50.
LavieL. Oxidative stress—a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis. 2009;51(4):303–312.
51.
MonneretDPepinJLGodin-RibuotD. Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima-media thickness in nonobese sleep apnea patients. Free Radic Biol Med. 2010;48(4):619–625.
52.
TanKCChowWSLamJC. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep. 2006;29(3):329–333.
53.
CalvinADAlbuquerqueFNLopez-JimenezFSomersVK. Obstructive sleep apnea, inflammation, and the metabolic syndrome. Metab Syndr Relat Disord. 2009;7(4):271–278.
54.
RidkerPMCookN. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16):1955–1959.
UrsavasAKaradagMRodopluEYilmaztepeAOralHBGozuRO. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration. 2007;74(5):525–532.
57.
OhgaENagaseTTomitaT. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol. 1999;87(1):10–14.
58.
El-SolhAAMadorMJSikkaPDhillonRSAmsterdamDGrantBJ. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest. 2002;121(5):1541–1547.
59.
IpMSLamKSHoCTsangKWLamW. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest. 2000;118(3):580–586.
60.
MacreaMMartinTHorowitzM. Leptin, hypoxia and metabolic syndrome in patients with obstructive sleep apnea. Intern Med. 2011;50(18):2079.
61.
SantilliFVazzanaNLianiRGuagnanoMTDaviG. Platelet activation in obesity and metabolic syndrome. Obes Rev. 2012;13(1):27-42.
62.
BokinskyGMillerMAultKHusbandPMitchellJ. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest. 1995;108(3):625–630.
63.
NenaEPapanasNSteiropoulosP. Mean platelet volume and platelet distribution width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity?Platelets. 2012;23(6):447–54.
64.
PapanasNSymeonidisGMaltezosE. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15(8):475–478.
65.
VarolEOzturkOGoncaT. Mean platelet volume is increased in patients with severe obstructive sleep apnea. Scand J Clin Lab Invest. 2010;70(7):497–502.
66.
McNicholasWTBonsigoreMR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007;29(1):156–178.
67.
von KanelRLoredoJSPowellFLAdlerKADimsdaleJE. Short-term isocapnic hypoxia and coagulation activation in patients with sleep apnea. Clin Hemorheol Microcirc. 2005;33(4):369–377.
68.
JagroopIAMikhailidisDP. Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl. Platelets. 2000;11(5):272–277.
69.
MaruyamaKMorishitaESekiyaA. Plasma levels of platelet-derived microparticles in patients with obstructive sleep apnea syndrome. J Atheroscler Thromb. 2012;19(1):98–104.
70.
von KanelRDimsdaleJE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest. 2003;124(5):1956–1967.
71.
AhmedMHByrneCD. Obstructive sleep apnea syndrome and fatty liver: association or causal link?World J Gastroenterol. 2010;16(34):4243–4252.
72.
TurkayCOzolDKasapogluBKirbasIYildirimZYigitogluR. Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir Care. 2012;57(2):244–9.
73.
NormanDBardwellWAArosemenaF. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep. 2008;31(1):121–126.
74.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?Curr Vasc Pharmacol. 2011;9(6):698–705.
KanbayAKayaEBuyukoglanH. Serum gamma-glutamyl transferase activity is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. Respir Med. 2011;105(4):637–642.
77.
KaragiannisAMikhailidisDPTziomalosK. Serum uric acid as an independent predictor of early death after acute stroke. Circ J. 2007;71(7):1120–1127.
78.
TsouliSGLiberopoulosENMikhailidisDPAthyrosVGElisafMS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?Metabolism. 2006;55(10):1293–1301.
79.
PialouxVHanlyPJFosterGE. Effects of exposure to intermittent hypoxia on oxidative stress and acute hypoxic ventilatory response in humans. Am J Respir Crit Care Med. 2009;180(10):1002–1009.
80.
Ruiz GarciaASanchez ArmengolALuque CrespoE. Blood uric acid levels in patients with sleep-disordered breathing [in Spanish]. Arch Bronconeumol. 2006;42(10):492–500.
81.
DragerLFLopesHFMaki-NunesC. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One. 2010;5(8):e12065.
82.
SaitoHNishimuraMShibuyaE. Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. Chest. 2002;122(5):1686–1694.
83.
GrunsteinRRStenlofKHednerJSjostromL. Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. Int J Obes Relat Metab Disord. 1995;19(6):410–418.
84.
SteiropoulosPKotsianidisINenaE. Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep. 2009;32(4):537–543.
